Biography

Jason C. Gallagher, Pharm.D., FCCP, BCPS is Clinical Professor, Temple University School of Pharmacy; Clinical Specialist in Infectious Diseases, Temple University Hospital; and Adjunct Professor of Pharmacology, Drexel University School of Medicine. He is also the program director of the PGY2 Residency in Infectious Diseases Pharmacy at Temple. Before working at Temple, Dr. Gallagher developed and managed an antimicrobial stewardship program at Hahnemann University Hospital in Philadelphia, PA and completed residencies in pharmacy practice at the Virginia Commonwealth University Health System and infectious diseases in the immunocompromised host at Duke University Medical Center. At Temple University, he teaches courses in ID pharmacotherapy and microbiology and is a codirector of the Advanced Clinical Practice Track at the School of Pharmacy. His research areas focus on the pharmacotherapy of resistant Gram-negative and Grampositive infections. He authored (with Dr. Conan MacDougall) three editions of Antibiotics Simplified, is co-editor of two editions of Frequently Prescribed *Medications – The Drugs You Need to Know*, and his work has been published in iournals including Pharmacotherapy, Clinical Infectious Diseases, Infectious Diseases in Clinical Practice, Expert Opinion on Pharmacotherapy, and BMC Infectious Diseases. He has served SIDP as a member of the Elections Committee, vice-chair of the Political Advocacy committee, and chair and vice-chair of the Inter-organizational Planning Committee. Dr. Gallagher has served as the Chair, Chair-Elect, and Secretary-Treasurer of the American College of Clinical Pharmacy Infectious Diseases Practice and Research Network (ACCP ID-PRN) and as President and

President-Elect of the Mid-Atlantic College of Clinical Pharmacy, a Philadelphiabased chapter of ACCP.

<u>Statement</u>

It is an honor to be nominated for the post of President-Elect of SIDP. I have been a member of SIDP since I was a resident and have directly benefitted from that membership in several ways, most directly when SIDP awarded me a grant to start our ID pharmacy residency six years ago. During the time of my membership I have watched our specialty evolve from one with pockets of excellent clinicians to one that is much more broad as antibiotic stewardship has been embraced throughout the nation and the world.

I believe we are at two turning points in ID pharmacotherapy where SIDP should be a critical component in the decision processes taking place. The first is the beginning of universal antimicrobial stewardship for US hospitals. Recent changes in California law and statements by the Centers for Disease Control are further evidence that the trend of antimicrobial stewardship program development is close to becoming a mandate. SIDP should be at the forefront of guiding government and regulatory agencies as they consider how best to address this likelihood, insuring that adequately trained ID pharmacists are integral components of these important programs.

The second is the combination of the continued drought of antibacterial development with the overlapping crisis of bacterial resistance. As public awareness has begun to increase on at least the latter of these issues, SIDP should work with partner organizations to increase pressure on legislators to address both of them. Should the several new antibiotics in late-stage development be approved, SIDP and its members will be integral in assuring their appropriate use. As importantly, we have the expertise to inform our colleagues and government representatives about fair reimbursement and logical use patterns that will encourage both increased utility for these drugs and further antibacterial development.

As my career has progressed, my interest in advocacy has increased. SIDP is as respected organization that can offer qualified opinions about many therapeutic and legislative issues. We must continue to advance the role of the ID pharmacist as we move forward, and it would be my honor to serve you and help do so.